This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this presentation that do not relate to matters of historical

REIMAGINING THE TREATMENT OF HEARING

LOSS Corporate Overview March 2021 Exhibit 99.1

This presentation contains

forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this presentation that do not relate to matters of historical fact should be considered forward-looking statements,

including without limitation statements regarding the interpretation and implications of the results of the topline, interim day-90 Phase 2a data and the FX-322-111 data, the timing and results of top-line data from the completed Phase 2a study as

well as the Phase 1b studies in age-related hearing loss and severe SNHL, the design and timing of future studies of and clinical development path for FX-322, the results and implications of the Phase 1/2 durability of response data, the timing of

end of phase 2 meetings with the FDA and future pivotal studies, the ability of our technology platform to provide patient benefit, the impact of COVID-19 on the Company's on-going and planned clinical trials and business, future milestone and

royalty payments under the license and collaboration agreement with Astellas Pharma Inc. ("Astellas"), the sufficiency of the Company's cash, cash equivalents and short-term investments, estimates of the size of the hearing loss

population and population at risk for hearing loss, estimates of the commercial opportunity of FX-322 and the impact on existing treatment paradigms, the timing of the remyelination program, and the potential application of the PCA platform to other

diseases. These forward-looking statements are based on management's current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause

actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: the impact of COVID-19

on the Company's ongoing and planned clinical trials, research and development and manufacturing activities, the relocation of the Company's offices and laboratory facilities, the Company's business and financial markets; Frequency

Therapeutics (the "Company") has incurred and will continue to incur significant losses and is not and may never be profitable; need for additional funding to complete development and commercialization of any product candidate; the

Company's dependence on the development of FX-322; the unproven approach of the PCA platform; the lengthy, expensive and uncertain process of clinical drug development and regulatory approval; limited experience successfully obtaining

marketing approval for and commercializing product candidates; the results of earlier clinical trials not being indicative of the results from later clinical trials; differences between preliminary or interim data and final data; adverse events or

undesirable side effects; disruptions at the FDA and other regulatory agencies; failure to identify additional product candidates; new or changed legislation; failure to maintain Fast Track designation for FX-322 and such designation failing to

result in faster development or regulatory review or approval; costly and damaging litigation, including related to product liability, intellectual property or brought by stockholders; dependence on Astellas Pharma Inc. for the development and

commercialization of FX-322 outside of the United States; misconduct by employees or independent contractors; reliance on third parties, including to conduct clinical trials and manufacture product candidates; compliance with laws and regulations,

including healthcare and environmental, health, and safety laws and regulations; failure to obtain, maintain and enforce protection of patents and other intellectual property; security breaches or failure to protect private personal information;

attracting and retaining key personnel; and ability to manage growth. These and other important factors discussed under the caption "Risk factors" in the Company's Form 10-Q filed with the Securities and Exchange Commission (SEC)

on November 16, 2020 and its other reports filed with the SEC could cause actual results to differ materially from those indicated by the forward-looking statements made in this presentation. Any such forward-looking statements represent

management's estimates as of the date of this presentation. While the Company may elect to update such forward-looking statements at some point in the future, it disclaims any obligation to do so, even if subsequent events cause its views to

change. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date of this presentation. Forward-Looking Statements and Other Disclaimers c Frequency Therapeutics,

c Frequency Therapeutics, Inc. 2021

- A Year of Data and Growth MOMENTUM CLARITY LEADERSHIP Working to advance the first restorative medicine for patients with sensorineural hearing loss Published clinical data in peer-reviewed journal show hearing improvements Charting clinical

and regulatory path forward Two single-dose studies of FX-322 now show statistically significant and clinically meaningful improvements in speech intelligibility Additional probing studies aim to explore potential of FX-322 in older and severe

populations Learnings from interim Phase 2a study read-out informs future studies; Company plans to advance single-dose administration Data from Phase 1b (111) study supportive of data seen in FX-322 Phase 1/2 study Continued Astellas Partnership

for ex-US development, commercialization

Frequency Therapeutics: Pioneering a

New Mode of Medicine c Frequency Therapeutics, Inc. Clinical-stage company that uses small molecules to activate progenitor cells within the body Two, independent clinical studies, show first-ever evidence of a hearing signal and hearing

restoration; potential to treat tens of millions of patients Transformative approach to regenerative medicine potentially for a broad range of degenerative diseases, including pre-clinical multiple sclerosis program Clinical-stage company that uses

small molecules to activate progenitor cells within the body to restore damaged cells and tissue

Hearing loss: the 4th largest cause of

disability globally c Frequency Therapeutics, Inc. Since 2014 Frequency has been developing a powerful new therapeutic approach to address a condition for which there has been limited innovation in decades. Frequency Therapeutics: A Vision Built on

Regeneration Source: Wilson, et al. Lancet. (2017)

c Frequency Therapeutics, Inc. Large

Hearing Loss Market: No Restorative Treatments $980 Billion Only 20% market penetration for Hearing Aids Lost annually due to untreated hearing loss globally* ~41 Million SNHL patients in US ~$10 Billion US hearing aid market annual sales *Source:

World Health Organization

I'M NOTICING AND UNDERSTANDING

WHAT YOU'RE SAYING. Intelligibility - The Major Unmet Clinical Need

High Frequencies are Critical for

Intelligibility For someone with high-frequency hearing loss, words may be indistinguishable - impacting their ability to understand and communicate.

c Frequency Therapeutics, Inc. of the

words in English rely on the use of High Frequency Consonants Of the words in Mandarin Of the words in Spanish 40% 42% 55%

July, 2020 "Hearing loss is

the largest potentially modifiable risk factor for developing dementia" Hearing Loss May Have a Significant Impact on Overall Health DEMENTIA DEPRESSION Increased risks with untreated hearing loss 50% 41% JAMA Nov 8, 2018 Deal J, et al.

Incident Hearing Loss and Comorbidity. A Longitudinal Administrative Claims Study.

"Analysis of hair cells,

auditory nerve fibers and strial tissues shows that the degree of hearing loss is well predicted from the amount of hair cell loss." - Journal of Neuroscience, July 2020 Sensory Hair Cells Progenitor Cells Missing Sensory Hair Cells

The Problem: Missing Sensory Hair Cells in the Cochlea

Solution: A Therapy to Address the

Underlying Pathology Activating progenitor cells to regenerate sensory hair cells in the cochlea

c Frequency Therapeutics, Inc.

Solution: Directly Targeting Regenerating Sensory Hairs in the Cochlea FX-322 is administered via a standard intratympanic injection, a common procedure ENTs perform routinely The injection concentrates FX-322 in the cochlear region that detects

extended high-frequency sounds, critical for speech intelligibility

c Frequency Therapeutics, Inc.

Increasing Focus on Higher-Level Hearing Benefit Intelligibility (Clarity) measured with word recognition and words-in-noise tests Word Recognition Test List of 50 monosyllabic words Single words played in quiet Words-in-Noise Test Background noise

from multiple voices Played at different signal-to-noise ratios Audibility (Loudness) measured with pure tone test (Standard, Validated Tests)

DOI: 10.1097/MAO.0000000000003120 c

Frequency Therapeutics, Inc. FX-322 Clinical Data Published in Leading Journal FX-322 Phase 1/2 and drug delivery studies Improved Speech Intelligibility in Subjects with Stable Sensorineural Hearing Loss Following Intratympanic Dosing of FX-322 in

a Phase 1b Study (W.J. McLean, et. al.) Peer-reviewed Pre-eminent journal in the field Editor: Larry Lustig, M.D. Chair, Department of Otolaryngology - Head & Neck Surgery at Columbia University

Phase 2a Interim (Day-90) Study

Confirms Dosing Regimen Top-line findings: FX-322 continues to have a favorable safety profile No treatment related SAEs reported Comparable AEs in placebo and FX-322 groups Treatment regimen using four weekly injections is unfavorable Creates an

environment within the ear diminishing ability to effectively demonstrate hearing signal Study design leads to hearing increases in placebo group that exceed our other studies and published standards Requiring subjects to have a word recognition

deficit suppressed scores at baseline (pre-treatment) No discernible hearing improvement over placebo observed Incidence higher across all groups than in single dose studies Company plans to advance single injection regimen moving forward Developing

plans to mitigate bias in future studies

Two Independent Studies (FX-322-201,

FX-322-111) Show Hearing Improvements with Single Dose FX-322-111 Study Overview Phase 1b safety study (FX-322-111) to evaluate impact of injections conditions on tolerability FX-322 injected in one ear - other ear acted as control Open-label,

multi-center, randomized study Mild to severe subjects FX-322-111 Study Results Hearing function tested 90 days post dosing 34% of subjects achieved 10% or greater absolute improvement in WR in treated ear Favorable safety profile Supportive of data

from published/peer-reviewed Phase 1/2 study

c Frequency Therapeutics, Inc.

Building on Existing Treatment Paradigms Without Therapeutics (Current State) With Therapeutics (Future State) ENT Audiologist Patient Journey ENT treatment role in diagnosis, cochlear implant or bone- anchored hearing aid Audiologist Diagnosis

Treatment Monitoring ENT Increased patient flow to AUD for diagnosis Hearing aid still dispensed by AUD Need for on-going monitoring by AUD Diagnosis, therapeutic administered by ENT Empowers ENT's with a therapeutic intervention Anticipate

Audiologists will see increased patient flow

c Frequency Therapeutics, Inc.

Understanding the Broader potential of FX-322 Phase 1b Study evaluating ages 18- 65 with severe hearing loss Phase 1b Study evaluating ages 66-85 with mild to moderately severe age- related hearing loss Phase 2a Study evaluating ages 18 - 65

with noise induced and sudden mild to moderately severe SNHL 5M severe 16M mild to moderate, age 65+ 20M mild to moderate, age 18-65 Source: NCHS Survey Data 2016-18; NCHS 2017; NCHS 2016; Each SNHL Type Being Studied in FX-322 clinical program

represents a significant patient population

c Frequency Therapeutics, Inc.

Program Momentum and Expansion Sensorineural Hearing Loss (SNHL) Remyelination in Multiple Sclerosis Day-90 data analysis shared March 2021, end of study read out in late Q2 2021 Study fully enrolled with 30 subjects, read out planned for Q2 2021

Study commenced in Q4 2020, read out planned for Q3 2021 DISCOVERY PRECLINICAL PHASE 1 PHASE 2 PHASE 3 DISCOVERY PRECLINICAL PHASE 1 PHASE 2 PHASE 3 FX-322 Phase 2a - 202 Study* Study of noise induced and sudden SNHL patients with mild to

moderately severe acquired SNHL, ages 18 - 65 FX-322 Phase 1b - 112 Study Study of mild to moderately severe age-related hearing loss patients, ages 66 - 85 FX-322 Phase 1b - 113 Study Study of patients with severe SNHL, ages 18

- 65 FX-322 Phase 1b - 111 Study* Open-label safety study focused on administration conditions for FX-322. Subjects had mild to severe SNHL, ages 18 - 65 Study enrolled with 33 subjects, completed March 2020 * Studies had interim

read outs, March 2020

c Frequency Therapeutics, Inc.

Regenerative Approach with Broad Potential Brain Eye Skin Bone Cartilage Muscle Intestine Lung Ear Potential to address a range of degenerative diseases Progenitor cells are stem cells that are pre-programmed to perform a specific

Remyelination is the major unmet

need in MS Little room to improve current immunomodulators Patients still decline due to lack of myelination Target population for remyelination represents 50% of MS patients Approach Single agents have demonstrated signal in early Phase 2 MS

studies Frequency has secured rights across multiple key classes of molecules Building on Frequency expertise in synergistic combinations of small molecules Remyelination Program for Multiple Sclerosis c Frequency Therapeutics, Inc.

c Frequency Therapeutics, Inc.

Summary and Financial Profile Well capitalized for advancement of pivotal trials. Runway into 2023 Ex-US Partnership with Strong Potential Milestones and Royalties $220.3 Million in Cash and Cash Equivalents* *As of Dec. 31, 2020. Excludes

restricted cash Addressing Broadest Potential SNHL Market FX-322 Near-Term Data Readouts Platform Potential Continued clinical validation and development progress towards pivotal studies Studies across all major SNHL types Addressable market of

>40 million people in the US PCA platform with potential to treat patients across numerous degenerative diseases

REIMAGINING THE TREATMENT OF HEARING

LOSS Corporate Overview March 2021

c Frequency Therapeutics, Inc.

c Frequency Therapeutics, Inc. Broad

Potential of Progenitor Cell Activation Approach

c Frequency Therapeutics, Inc. Origin

of Frequency Therapeutics Tissue-Specific, Pre-programmed Stem Cells Decoding Intestinal Regeneration Langer and Karp publish small molecules activate intestinal progenitors Enabling Cochlear Regeneration Same cues reactivate normally inactive